LENZ Therapeutics (LENZ) Current Assets (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Current Assets data on file, last reported at $268.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $268.4 million, up 35.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $268.4 million (up 35.64% YoY), and the FY2025 annual result was $301.4 million, up 42.23% from the prior year.
• Current Assets declined to $268.4 million in Q1 2026 per LENZ's latest filing, from $301.4 million in the prior quarter.
• Over five years, Current Assets peaked at $343.8 million in Q1 2022 and troughed at $67.2 million in Q4 2023.
• A 5-year average of $241.7 million and a median of $238.8 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets plunged 75.58% in 2023, then soared 215.15% in 2024.
• A 5-year view of Current Assets shows it stood at $275.4 million in 2022, then sank by 75.58% to $67.2 million in 2023, then soared by 215.15% to $211.9 million in 2024, then surged by 42.23% to $301.4 million in 2025, then retreated by 10.96% to $268.4 million in 2026.
• Business Quant data shows LENZ's Current Assets at $268.4 million in Q1 2026, $301.4 million in Q4 2025, and $207.0 million in Q3 2025.